Discovery Life Sciences and outsourced research network provider Scientist.com are joining forces on technology services aiding liquid biopsy and immunotherapy studies.
Through the new offering, Illumina's TruSight Oncology 500 (TSO500) technology for formalin-fixed paraffin-embedded (FFPE) and circulating tumor DNA (ctDNA) services will be made available to Scientist.com users. The TSO500 technology has been incorporated into Discovery's HudsonAlpha Discovery sequencing and bioinformatics laboratory, and is available under one umbrella legal agreement, the companies noted.
